Read More Guidance News Ligand Pharmaceuticals Sees FY22 Royalties $62M-$66M By Benzinga Newsdesk August 8, 5:09 PM 2022 Financial Guidance Ligand is raising 2022 revenue guidance for the combined business and is reaffirming revenue estimated to be attributable to the OmniAb business anticipating the spin-off occurs LGND
Read More News NYSE Says To Require COVID-19 Vaccines For Access To Trading Floor By Michael Horton August 11, 1:53 PM -Bloomberg Citing CNBC SPY
Read More Analyst Ratings News Price Target Piper Sandler Maintains Overweight on Adobe, Lowers Price Target to $345 By Benzinga Newsdesk October 17, 4:30 AM Piper Sandler analyst Brent Bracelin maintains Adobe (NASDAQ:ADBE) with a Overweight and lowers the price target from $358 to $345. ADBE
Read More Government News NHTSA Says Investigation Into Tesla’s Autopilot, Associated Vehicle Systems Remains Open And Active By Michael Horton February 16, 2:05 PM -Reuters TSLA